MedPath

Tagged News

PHASE Scientific Launches World's Largest Urine-Based HPV Screening Study with 17,000 Participants

AI
  • PHASE Scientific has launched the world's largest clinical study for urine-based cervical cancer screening, enrolling 17,000 women in China to evaluate their proprietary PHASiFY™ technology.
  • The study sets three world records including the largest urine-based HPV screening trial and the first validation of urine-based methylation testing for cervical cancer detection.
  • PHASiFY™ technology achieves 93.42% sensitivity for high-risk HPV detection by concentrating HPV DNA in urine by more than 10,000 times.
  • The research addresses China's low screening coverage rate of 51.5% among women aged 35-64, well below WHO's 70% benchmark target.

Iranian Researchers Develop AI-Powered Personalized mRNA Vaccine for Lung Cancer

AI
  • Iranian scientists at Tehran University of Medical Sciences have unveiled the first personalized mRNA vaccine for lung cancer that uses artificial intelligence algorithms to tailor treatment to individual tumor genetics.
  • The innovative vaccine can reduce development time by up to 90 percent, with design and production completed in just two to three weeks compared to traditional methods requiring years.
  • Built on the same mRNA platform as COVID-19 vaccines, the smart vaccine identifies optimal candidates before clinical phases using genetic data and AI predictions rather than trial-and-error approaches.
  • While still in research phase with no foreign counterpart, clinical trials are expected to take at least two to three years before potential international launch.

GeneDx Strengthens Leadership Team with Key Appointments to Advance AI-Powered Precision Medicine

AIPrecision MedicineRare DiseaseDrug Discovery
  • GeneDx appointed Lisa Gurry as Chief Business Officer to lead strategic partnerships and unlock the potential of GeneDx Infinity, the world's largest rare disease dataset with nearly one million exomes and genomes.
  • The company also named Dr. Thomas Fuchs, Chief AI Officer at Eli Lilly, to its board of directors to advance AI applications in genomic medicine and drug discovery.
  • These appointments position GeneDx to accelerate precision medicine initiatives, leveraging AI tools like Multiscore and recent acquisitions such as Fabric Genomics to improve diagnostic efficiency.
  • The strategic moves aim to enhance partnerships with biopharma companies and health systems while delivering faster, more accurate rare disease diagnoses for patients and families.

Immuto Scientific Secures $8M Funding and Daiichi Sankyo Partnership to Advance AI-Driven Cancer Target Discovery

AIOncology
  • Immuto Scientific closed an oversubscribed $8 million Seed 2 financing round led by DYDX to advance its AI-enabled structural surfaceomics platform for drug discovery.
  • The company announced a collaboration with Daiichi Sankyo to discover new cancer-specific cell-surface targets in solid tumors using proprietary structural proteomics technology.
  • Immuto's platform identifies disease-specific surface protein conformations invisible to conventional omics approaches, potentially enabling development of first-in-class therapies with improved selectivity.
  • The funding will support advancement of the company's internal oncology pipeline toward IND-enabling studies and platform expansion into immunology and inflammation.

GSK Commits $30 Billion U.S. Investment to Advance Respiratory and Cancer Medicine Manufacturing

OncologyAI
  • GSK announced a $30 billion investment across the United States over five years, focusing on research and development and supply chain infrastructure to strengthen life sciences capabilities.
  • The investment includes $1.2 billion for advanced manufacturing facilities and AI technologies, featuring a new biologics flex factory in Pennsylvania targeting respiratory diseases and cancer treatments.
  • Construction of the Upper Merion facility will commence in 2026, designed to produce next-generation medicines for COPD, asthma, and various cancer types including hematological and solid tumors.
  • The initiative will create hundreds of highly skilled jobs and positions the U.S. as GSK's top global location for clinical trials and research studies over the next five years.

Roche Integrates AI-Enabled Accu-Chek SmartGuide CGM with mySugr App Following CE Mark Approval

AI
  • Roche announced the integration of its Accu-Chek SmartGuide continuous glucose monitoring solution with the mySugr diabetes management app, providing AI-enabled predictive capabilities for diabetes patients.
  • The SmartGuide CGM solution received CE Mark approval and exceeded high performance requirements in all advanced predictive features during clinical evaluations.
  • Real-world evidence from the rollout was presented at the European Association for the Study of Diabetes annual meeting, demonstrating the solution's clinical effectiveness.
  • The integration aims to simplify daily decision-making by visualizing and analyzing therapy data in one centralized platform for improved diabetes management.

METiS TechBio Launches AI-Powered NanoForge Platform to Transform Drug Delivery

AI
  • Beijing-based biotech unicorn METiS TechBio unveiled NanoForge, described as the world's first AI-powered nano delivery platform that combines advanced AI models with computer simulations and lab experiments.
  • The platform has generated over 10 million lipid structures and demonstrated targeted delivery across eight human organ types, including liver, lungs, heart, muscles, tumors, central nervous system, and gastrointestinal tract.
  • METiS has built a robust drug pipeline with more than 10 advanced programs, including seven validated in preclinical studies and four in clinical trials, with the most advanced oncology candidate reaching pre-NDA stage.
  • The company has secured over 100 patents to protect its proprietary technology and aims to address the longstanding pharmaceutical challenge of precise drug delivery without harming healthy tissues.

Parexel Forms Strategic AI Partnerships to Accelerate Drug Development and Clinical Trial Efficiency

AI
  • Parexel has announced two strategic AI partnerships with Weave Bio and Paradigm Health to revolutionize clinical trial operations and regulatory submission processes.
  • The partnership with Weave Bio has already demonstrated 50% faster completion times for Investigational New Drug applications using their AutoIND platform.
  • Collaboration with Paradigm Health aims to address the $2.23 billion average cost of bringing new therapies to market through AI-driven trial optimization.
  • These partnerships position Parexel to offer sponsors compressed timelines, lower operational costs, and improved patient access to clinical trials.

Conceivable Life Sciences Raises $50 Million Series A to Commercialize AI-Powered Automated IVF Laboratory

AI
  • Conceivable Life Sciences secured $50 million in Series A funding led by Advance Venture Partners to accelerate development of AURA, the world's first AI-powered automated IVF laboratory platform.
  • The company's AURA platform uses robotic precision and AI algorithms to standardize over 200 intricate IVF workflow steps, aiming to reduce variability and improve pregnancy outcomes compared to traditional manual processes.
  • Clinical results show promise with 18 healthy babies from an earlier prototype study and ongoing positive pregnancy results from a current 100-patient pilot trial.
  • The funding will support U.S. commercial launch in 2026, addressing critical industry challenges including rising demand, limited clinic capacity, and cost barriers affecting IVF accessibility.

ProofPilot Acquires Lokavant to Enhance Clinical Trial Performance with AI-Powered Predictive Analytics

AI
  • ProofPilot has acquired Lokavant, a clinical trial intelligence company spun out of Roivant in 2020, to integrate advanced predictive analytics into clinical trial execution.
  • The combined platform leverages AI-powered forecasting to help sponsors and CROs reduce non-conformance events by 70% and improve forecasting accuracy by 70x.
  • Lokavant's Spectrum solution delivers real-time forecasts with over 80% confidence, enabling clinical teams to anticipate challenges and optimize study performance.
  • The acquisition creates an end-to-end platform that combines digital trial planning, execution, and predictive intelligence to accelerate therapy delivery to patients.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.